SALT LAKE CITY, Jan. 18, 2011 /PRNewswire/ -- TechniScan
(OTC Bulletin Board: TSNI), a medical device company engaged in the
development and commercialization of an automated 3D breast
ultrasound imaging system, announced today that it has signed a
Product Development Agreement with Austin, Texas based Womens3D, Inc. worth a
minimum of $1.5 million.
TechniScan and Womens3D will co-develop technology specifically
for Womens3D's proposed target market that is directed toward
women's health practices.
Under the terms of the agreement, Womens3D acquired a prototype
of the TechniScan WBU system for $250,000 and contemplates contributing at least
$1.25 million more to support
development of a specialized whole breast ultrasound imaging system
based on the TechniScan Warm Bath Ultrasound (WBU) product now in
clinical testing. In addition, TechniScan will supply technical
support of the product and customization of the imaging network
applications that will be used in part to store and transmit the
image files.
"As a part of the Development Agreement, we purchased a
prototype WBU system for evaluation, and we are now very excited to
be working with TechniScan and welcome their expertise as we
address the needs of the developing markets in women's health,"
said Scott Sanders, chief executive
officer of Womens3D.
Womens3D's Chief Science Officer, Mark
Lenox, Ph.D., formerly part of the engineering team that
performed the research and early development and commercialization
of Positron Emission Tomography (PET) in nuclear medical imaging,
conducted the technical evaluation of TechniScan's WBU system.
TechniScan's Warm Bath Ultrasound (WBU) system is designed to
capture three-dimensional images of the breast as a woman lies
prone on a table while proprietary ultrasound technology in a warm
water tank images the breast anatomy. This new method of
imaging produces diagnostic information that is not available with
traditional hand-held ultrasound or whole breast ultrasound systems
presently on the market.
"TechniScan is excited to be working with Womens3D on this
development program, which potentially will open new markets for
our equipment and add a valuable partner to our development
efforts. Over the next one to two years we expect to complete
the development of an ultrasound system for Womens3D
based on our technology," said Dave
Robinson, chief executive officer of TechniScan.
A more complete and detailed description of the Product
Development Agreement is set forth in TechniScan's current report
on Form 8-K filed today with the Securities and Exchange
Commission.
About TechniScan
TechniScan, Inc., is a medical device company engaged in the
development and commercialization of a non-invasive imaging tool
designed to provide physicians with automated ultrasound images of
the human breast. TechniScan's WBU™ imaging device is limited by
U.S. law to investigational use, unless and until cleared by the
FDA. For more information, please visit www.tsni.com.
About Womens3D
Womens3D, Inc., is an early stage medical device company engaged
in the development and commercialization of imaging solutions
designed to provide women's health practices with powerful new
tools that can deliver rapid and clinically effective diagnostic
breast imaging at the point of care. For more information
please visit www.Womens3D.com.
Forward-Looking Statements Certain statements
in this press release that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements may
be identified by the use of words such as "anticipate," "believe,"
"expect," "future," "may," "will," "would," "should," "plan,"
"projected," "potential," "intend," and similar expressions.
Such forward-looking statements involve known and unknown
risks, uncertainties, and other factors that may cause the actual
results, performance, or achievements of TechniScan, Inc. (the
"company") to be materially different from those expressed or
implied by such forward-looking statements. The company's
future operating results are dependent upon many factors, including
risk factors discussed in the company's periodic filings with the
Securities and Exchange Commission, which are available for review
at www.sec.gov, including the company's Annual Report on Form 10-K
filed on March 22, 2010. The company
undertakes no obligation to update any forward-looking statement,
whether as a result of new information, future events, or
otherwise.
For More
Information:
Dave Robinson
TechniScan Medical
Systems
(801) 994-2965
drobinson@tsni.com
|
|
|
SOURCE TechniScan